Sensei Biotherapeutics (NASDAQ:FTH) Shares Gap Down – What’s Next?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) gapped down prior to trading on Thursday. The stock had previously closed at $21.51, but opened at $19.90. Sensei Biotherapeutics shares last traded at $21.0450, with a volume of 6,898 shares traded.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. TD Cowen assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 9th. They issued a “buy” rating on the stock. Citizens Jmp began coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $51.00 target price for the company. William Blair began coverage on shares of Sensei Biotherapeutics in a research note on Friday. They issued an “outperform” rating for the company. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target for the company. Finally, Raymond James Financial started coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They issued an “outperform” rating and a $56.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Price Performance

The stock has a market cap of $485.79 million, a PE ratio of -0.13 and a beta of -0.29. The firm’s 50-day moving average price is $31.39.

Sensei Biotherapeutics (NASDAQ:FTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Analysts expect that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A number of institutional investors have recently made changes to their positions in FTH. Vivo Capital LLC bought a new position in shares of Sensei Biotherapeutics during the 1st quarter valued at $22,758,000. Stempoint Capital LP bought a new stake in Sensei Biotherapeutics in the first quarter worth $4,188,000. Alyeska Investment Group L.P. purchased a new stake in Sensei Biotherapeutics during the second quarter valued at about $3,610,000. Bank of America Corp DE boosted its position in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after buying an additional 32,719 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Sensei Biotherapeutics by 178.2% during the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the period. Hedge funds and other institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.